241 related articles for article (PubMed ID: 32298853)
1. Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity.
Szefler SJ; Casale TB; Haselkorn T; Yoo B; Ortiz B; Kattan M; Busse WW
J Allergy Clin Immunol Pract; 2020 Sep; 8(8):2673-2680.e3. PubMed ID: 32298853
[TBL] [Abstract][Full Text] [Related]
2. Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy During the Fall Season Among Children with Persistent Asthma.
Sheehan WJ; Krouse RZ; Calatroni A; Gergen PJ; Gern JE; Gill MA; Gruchalla RS; Khurana Hershey GK; Kattan M; Kercsmar CM; Lamm CI; Little FF; Makhija MM; Searing DA; Zoratti E; Busse WW; Teach SJ;
J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3021-3028.e2. PubMed ID: 32376491
[TBL] [Abstract][Full Text] [Related]
3. Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations.
Busse WW; Szefler SJ; Haselkorn T; Iqbal A; Ortiz B; Lanier BQ; Chipps BE
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1201-1211. PubMed ID: 33223095
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
[TBL] [Abstract][Full Text] [Related]
5. Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma.
Busse WW; Humbert M; Haselkorn T; Ortiz B; Trzaskoma BL; Stephenson P; Garcia Conde L; Kianifard F; Holgate ST
Ann Allergy Asthma Immunol; 2020 Feb; 124(2):190-196. PubMed ID: 31760132
[TBL] [Abstract][Full Text] [Related]
6. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
[TBL] [Abstract][Full Text] [Related]
7. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis.
Busse WW; Wenzel SE; Casale TB; FitzGerald JM; Rice MS; Daizadeh N; Deniz Y; Patel N; Harel S; Rowe PJ; Graham NMH; O'Riordan T; Pavord ID
Lancet Respir Med; 2021 Oct; 9(10):1165-1173. PubMed ID: 34181876
[TBL] [Abstract][Full Text] [Related]
8. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
9. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.
Casale TB; Chipps BE; Rosén K; Trzaskoma B; Haselkorn T; Omachi TA; Greenberg S; Hanania NA
Allergy; 2018 Feb; 73(2):490-497. PubMed ID: 28859263
[TBL] [Abstract][Full Text] [Related]
10. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
[TBL] [Abstract][Full Text] [Related]
11. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
[TBL] [Abstract][Full Text] [Related]
12. Response to Omalizumab in Black and White Patients with Allergic Asthma.
Szefler SJ; Jerschow E; Yoo B; Janampally P; Pazwash H; Holweg CTJ; Hudes G
J Allergy Clin Immunol Pract; 2021 Nov; 9(11):4021-4028. PubMed ID: 34303017
[TBL] [Abstract][Full Text] [Related]
13. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
Respir Med; 2019; 154():69-75. PubMed ID: 31220806
[TBL] [Abstract][Full Text] [Related]
14. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
[TBL] [Abstract][Full Text] [Related]
15. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.
Teach SJ; Gill MA; Togias A; Sorkness CA; Arbes SJ; Calatroni A; Wildfire JJ; Gergen PJ; Cohen RT; Pongracic JA; Kercsmar CM; Khurana Hershey GK; Gruchalla RS; Liu AH; Zoratti EM; Kattan M; Grindle KA; Gern JE; Busse WW; Szefler SJ
J Allergy Clin Immunol; 2015 Dec; 136(6):1476-1485. PubMed ID: 26518090
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.
Casale TB; Luskin AT; Busse W; Zeiger RS; Trzaskoma B; Yang M; Griffin NM; Chipps BE
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):156-164.e1. PubMed ID: 29800752
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab in Asthma with Fixed Airway Obstruction: Post Hoc Analysis of EXTRA.
Hanania NA; Fortis S; Haselkorn T; Gupta S; Mumneh N; Yoo B; Holweg CTJ; Chipps BE
J Allergy Clin Immunol Pract; 2022 Jan; 10(1):222-228. PubMed ID: 34419680
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
[TBL] [Abstract][Full Text] [Related]
19. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis.
Fu Z; Xu Y; Cai C
J Asthma; 2021 Oct; 58(10):1350-1358. PubMed ID: 32602383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
